LMMY — Exousia Bio, Inc.
—
OTC ·
Unknown ·
Unknown ·
CIK 1939937 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Nov 2025 | 0 | -62,108 | -237,005 | -19,083 | 22,050,670 | 0 | 261,023 |
| Aug 2025 | 0 | 0 | -31,814 | -31,814 | 0 | 0 | 35,314 |
| Feb 2025 | 0 | 0 | -23,827 | 61,833 | 0 | 0 | 0 |
| Nov 2024 | 0 | 0 | -6,981 | 80,129 | 24,854 | 1,028 | 0 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$170,912
Investing CF
$-22,054,346
Financing CF
$21,874,043
CapEx
—
Dividends Paid
—
Buybacks
$-3,500
EPS Diluted TTM
$0.01
As of
2026-06-21
Balance + Analyst (yfinance extras)
Retained Earnings
$-288,623
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-299,627
Pretax Income TTM
$91,115
Interest Exp TTM
$0
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-280,586
Free Cash Flow
—
Enterprise Value
—
Total Cash
—
Total Debt
$0
Shares Out
52,500,000
Trailing EPS
$0.00
Book Value
$0.31
ROE
-0.7%
ROA
-1.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| May 2025 | — | — | — | — | — | — | — |
| May 2024 | 11,500 | -26,243 | -25,807 | 27,453 | 82,348 | — | -12,484 |
| May 2023 | 0 | -56,421 | -56,421 | 37,044 | 66,132 | — | -38,111 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SPY | SPDR S&P 500 ETF TRUST | $692.88B | $754.95 | — |
| KLAC | KLA CORP | $302.43B | $231.52 | — |
| QQQ | INVESCO QQQ TRUST, SERIES 1 | $285.20B | $725.51 | — |
| IBM | INTERNATIONAL BUSINESS MACHINES CORP | $270.27B | $287.56 | — |
| KXIAY | Kioxia Holdings Corporation/ADR | $266.29B | $48.66 | — |
News headlines (Yahoo Finance, 1h cache)
Renowned Immunologist and Urological Surgeon Dr. Marvin Hausman Featured in New Exousia Bio, Inc. Interview
2025-12-04 13:30 · Yahoo
Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms
2025-12-02 18:45 · Yahoo
LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.
2025-12-02 15:28 · Yahoo
Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value
2025-11-17 20:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.